JP2021521201A - 骨髄異形成症候群を予防または治療するためのｂｓｔ１に対する抗体 - Google Patents

骨髄異形成症候群を予防または治療するためのｂｓｔ１に対する抗体 Download PDF

Info

Publication number
JP2021521201A
JP2021521201A JP2020555884A JP2020555884A JP2021521201A JP 2021521201 A JP2021521201 A JP 2021521201A JP 2020555884 A JP2020555884 A JP 2020555884A JP 2020555884 A JP2020555884 A JP 2020555884A JP 2021521201 A JP2021521201 A JP 2021521201A
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
bst1
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020555884A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019197609A5 (https=
JP2021521201A5 (https=
Inventor
ダニエラ ベラローサ
ダニエラ ベラローサ
コラード カッリージ
コラード カッリージ
アンドレア ペラカーニ
アンドレア ペラカーニ
クリスティアン ロールフ
クリスティアン ロールフ
ジェイムズ エドワード アクロイド
ジェイムズ エドワード アクロイド
モニカ ビナスキ
モニカ ビナスキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Chemie AG
Original Assignee
Berlin Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie AG filed Critical Berlin Chemie AG
Publication of JP2021521201A publication Critical patent/JP2021521201A/ja
Publication of JPWO2019197609A5 publication Critical patent/JPWO2019197609A5/ja
Publication of JP2021521201A5 publication Critical patent/JP2021521201A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2020555884A 2018-04-13 2019-04-12 骨髄異形成症候群を予防または治療するためのｂｓｔ１に対する抗体 Withdrawn JP2021521201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1806084.8A GB201806084D0 (en) 2018-04-13 2018-04-13 Antibodies
GB1806084.8 2018-04-13
PCT/EP2019/059420 WO2019197609A1 (en) 2018-04-13 2019-04-12 Antibodies against bst1 for preventing or treating myelodysplastic syndrome

Publications (3)

Publication Number Publication Date
JP2021521201A true JP2021521201A (ja) 2021-08-26
JPWO2019197609A5 JPWO2019197609A5 (https=) 2022-04-19
JP2021521201A5 JP2021521201A5 (https=) 2022-04-19

Family

ID=62203296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555884A Withdrawn JP2021521201A (ja) 2018-04-13 2019-04-12 骨髄異形成症候群を予防または治療するためのｂｓｔ１に対する抗体

Country Status (7)

Country Link
US (1) US20210032360A1 (https=)
EP (1) EP3773917A1 (https=)
JP (1) JP2021521201A (https=)
CN (1) CN111971091A (https=)
GB (1) GB201806084D0 (https=)
TW (1) TW201943732A (https=)
WO (1) WO2019197609A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201711785D0 (en) * 2017-07-21 2017-09-06 Berlin-Chemie Ag Antibodies
CN112630438B (zh) * 2021-03-08 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
CN119301155A (zh) * 2022-07-19 2025-01-10 百进生物科技公司 抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005295921A (ja) * 2004-04-14 2005-10-27 Pharma Design Inc 新規ｂｓｔ１選択的スプライシング変異体及びその用途
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
UA114478C2 (uk) * 2011-06-28 2017-06-26 Берлін-Хемі Аг Антитіло, яке специфічно зв'язується з bst1

Also Published As

Publication number Publication date
US20210032360A1 (en) 2021-02-04
WO2019197609A1 (en) 2019-10-17
TW201943732A (zh) 2019-11-16
EP3773917A1 (en) 2021-02-17
CN111971091A (zh) 2020-11-20
GB201806084D0 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
JP6141638B2 (ja) カドヘリン−１７に特異的な抗体
US20150093392A1 (en) Antibodies
US10982005B2 (en) Antibodies to bone marrow stromal antigen 1
JP6247209B2 (ja) Ａｄｐリボシルシクラーゼ２に対する抗体
JP2021521201A (ja) 骨髄異形成症候群を予防または治療するためのｂｓｔ１に対する抗体
US20120231004A1 (en) Antibodies
JP2020527594A (ja) 抗ｂｓｔ−１抗体及びシチジン類似体を含む医薬組合せ
HK1196138A (en) Antibodies to adp-ribosyl cyclase 2
HK1196138B (en) Antibodies to adp-ribosyl cyclase 2
RS56431B1 (sr) Antitela protiv adp-ribozil ciklaze 2
OA16799A (en) Antibodies to ADP-ribosyl cyclase 2.

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210930

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220411

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220629